Home

însăila metrou Băţ cd 38 Onorabil precedent ridica

Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma: Trends in Cancer
Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma: Trends in Cancer

Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents

The CD38 glycohydrolase and the NAD sink: implications for pathological conditions | American Journal of Physiology-Cell Physiology
The CD38 glycohydrolase and the NAD sink: implications for pathological conditions | American Journal of Physiology-Cell Physiology

Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis - ScienceDirect
Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis - ScienceDirect

FITC Mouse Anti-Human CD38
FITC Mouse Anti-Human CD38

Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

CD38 and CD157: A long journey from activation markers to multifunctional molecules - Quarona - 2013 - Cytometry Part B: Clinical Cytometry - Wiley Online Library
CD38 and CD157: A long journey from activation markers to multifunctional molecules - Quarona - 2013 - Cytometry Part B: Clinical Cytometry - Wiley Online Library

Simplified diagram representing of the structure of CD38 and its... | Download Scientific Diagram
Simplified diagram representing of the structure of CD38 and its... | Download Scientific Diagram

Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar

Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation - RSC Advances (RSC Publishing) DOI:10.1039/D1RA06266B
Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation - RSC Advances (RSC Publishing) DOI:10.1039/D1RA06266B

Frontiers | Targeting CD38 for acute leukemia
Frontiers | Targeting CD38 for acute leukemia

Frontiers | CD38: A Significant Regulator of Macrophage Function
Frontiers | CD38: A Significant Regulator of Macrophage Function

Frontiers | The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Frontiers | The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity | PLOS ONE
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity | PLOS ONE

CD38 and Regulation of the Immune Response Cells in Cancer
CD38 and Regulation of the Immune Response Cells in Cancer

CD38, A Target for Immunotherapeutic Approaches in Cancer
CD38, A Target for Immunotherapeutic Approaches in Cancer

CD38 in the age of COVID-19: a medical perspective | Physiological Reviews
CD38 in the age of COVID-19: a medical perspective | Physiological Reviews

PDF] ROLE OF CD 38 IN AGING AND CANCER : A REVIEW | Semantic Scholar
PDF] ROLE OF CD 38 IN AGING AND CANCER : A REVIEW | Semantic Scholar

CASI Pharmaceuticals | CID-103
CASI Pharmaceuticals | CID-103

Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells | Molecular Pharmaceutics
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells | Molecular Pharmaceutics